

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

Expedient Preparation of 4,6-Dihalo-3-arylisobenzofuran-1(3H)-ones from 3,5-Dihalo-*N*-ethylbenzamides

Lynn M. Bradley^a; Carleton G. Collins^a; Erica R. Tabakin^a; David A. Hunt^a

^a Department of Chemistry, The College of New Jersey, Ewing, New Jersey, USA

Online publication date: 07 April 2010

To cite this Article Bradley, Lynn M. , Collins, Carleton G. , Tabakin, Erica R. and Hunt, David A.(2010) 'Expedient Preparation of 4,6-Dihalo-3-arylisobenzofuran-1(3H)-ones from 3,5-Dihalo-*N*-ethylbenzamides', *Organic Preparations and Procedures International*, 42: 2, 187 – 190

To link to this Article: DOI: 10.1080/00304941003727045

URL: <http://dx.doi.org/10.1080/00304941003727045>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Expedient Preparation of 4,6-Dihalo-3-arylisobenzofuran-1(3H)-ones from 3,5-Dihalo-*N*-ethylbenzamides

Lynn M. Bradley, Carleton G. Collins, Erica R. Tabakin,
and David A. Hunt

Department of Chemistry, The College of New Jersey, Ewing, New Jersey, USA


3,5-Dihalobenzoic acid derivatives have long been known as scaffolds for compounds exhibiting a variety of biological activities. For example, compounds incorporating this moiety exhibit phytotoxicity,¹ selective inhibition of 11 β -HSD1 for the treatment of metabolic syndrome,² MCH 1 receptor antagonism,³ and serve as intermediates in the preparation of liquid crystals, fungicides, organo-tin antitumor compounds, insecticides, and quinolones possessing antibiotic activity.⁴

While our previous studies have shown that 3,5-dichloro tertiary benzamides are metalated *para* to the carboxamide group,⁵ we have found that use of secondary amides derived from 3,5-dihalobenzoic acids (**1**, X = Cl, F) result in exclusive *ortho*-metalation. In light of the paucity of methods available to prepare highly ring-functionalized derivatives of 3,5-dihalobenzoic acids, coupled with recent studies documenting the unique antitumor properties of benzolactones,⁶ we now describe the application of the chelation-controlled directed *ortho*-metalation reaction in this series as a useful method for the preparation of 4,6-dihalo-3-arylisobenzofuran-1(3H)-ones.

Metalation of 3,5-dihalo secondary benzamides (**1**) with *sec*-butyllithium resulted in exclusive *ortho*-directed metalation. Use of an aromatic aldehyde as the electrophile results in a lithioalkoxy intermediate (**3**) which undergoes nucleophilic attack upon the adjacent amide carbonyl during work-up with a concomitant loss of ethylamine, resulting in the formation of an aryl substituted dihalobenzofuranone (**4**, Table 1). This methodology should be applicable to a wide variety of both aromatic and aliphatic aldehydes based on reported reactions of aldehydes with aryllithium reagents generated by the directed *ortho*-metalation strategy.⁷ Studies of these systems as well as the scope and limitations of this process will be the focus of future investigations.

Submitted June 26, 2009.

Address correspondence to Lynn M. Bradley, Department of Chemistry, The College of New Jersey, P. O. Box 7718, Ewing, NJ 08628-0718, USA. E-mail: bradley@tcnj.edu



Experimental Section

Tetrahydrofuran was purchased as anhydrous (Fluka) and was stored under nitrogen. *sec*-Butyllithium (1.3 M in cyclohexane/hexane) was purchased from Acros Organics (the actual concentration was determined by colorimetric titration⁸ prior to use). ¹H NMR (300 MHz) and ¹³C NMR (75 MHz) data were acquired in CDCl₃ on a Varian Gemini 300 nuclear magnetic resonance spectrometer using tetramethylsilane (TMS) as internal standard CDCl₃ lock. IR data were determined from a Perkin-Elmer Model Spectrum 2000 FT-IR spectrometer. GC/MS data were obtained from an Agilent Technologies 6850 GC/5973 MSD. Microanalyses were carried out by Quantitative Technologies, Inc., Whitehouse, NJ. All melting points were determined on a Mel-Temp heating block apparatus and are uncorrected.

General Procedure

The 3,5-dihalo-N-ethylbenzamide (1 mmol), anhydrous THF (5 mL), and TMEDA (290 mg; 2.5 mmol) in anhydrous THF (5 mL) were charged to a 100 mL three-neck oven-dried flask equipped with a stir bar, nitrogen inlet, and low temperature thermocouple. The mixture was cooled to -78°C using a Dry Ice/acetone bath, and *sec*-butyllithium (2.5 equivalents relative to the starting benzamide) was added while the temperature was maintained below -70°C . The reaction mixture was stirred for 30 min at which point a solution of 1.5 equivalent of the aromatic aldehyde in anhydrous THF (2 mL) was added, it was allowed to warm to room temperature overnight under nitrogen

Table 1
Preparation of 4,6-Dihalo-3-arylisobenzofuran-1(3H)-ones

Compound	X	Ar	Yield (%)
4a	Cl	phenyl	90
4b	F	phenyl	88
4c	Cl	2-furyl	91
4d	F	2-furyl	64
4e	Cl	2-thienyl	97
4f	F	2-thienyl	77
4g	Cl	<i>p</i> -anisyl	73
4h	F	<i>p</i> -anisyl	98

and was quenched with water (100 mL). The mixture was then extracted with ethyl acetate (3 × 40 mL), with occasional use of a saturated sodium chloride solution (35 mL) to alleviate emulsion formation. The organic layer was washed with a solution of saturated ammonium chloride (40 mL), dried (MgSO₄), filtered, and concentrated *in vacuo* to afford the crude product. Purification was achieved by chromatography on silica gel (9:1 hexanes/MTBE), recrystallization, trituration (hexanes/MTBE), or a combination of trituration/chromatography.

4,6-Dichloro-3-phenylisobenzofuran-1(3H)-one (4a) was isolated as a white solid (chromatography), mp. 118–120°C; IR: 1776 (lactone) cm⁻¹; ¹H NMR (CDCl₃): δ 7.85 (d, *J*_{m-H} = 1.7 Hz, 1, ArH), 7.60 (d, *J*_{m-H} = 1.7 Hz, 1, ArH), 7.40–7.16 (m, 5, ArH), 6.35 (s, 1, CHO). ¹³C nmr (CDCl₃): δ 168.1, 144.9, 137.1, 135.0, 133.8, 130.8, 130.1, 129.9, 129.2, 128.4, 124.4, 82.7. Mass Spec: *m/z* = 279 (M⁺).

Anal. Calcd for C₁₄H₈Cl₂O₂: C, 60.24; H, 2.89. Found: C, 60.46; H, 2.71.

4,6-Difluoro-3-phenylisobenzofuran-1(3H)-one (4b) was isolated as a pale yellow solid (trituration), mp. 70–72°C. IR: 1765 (lactone) cm⁻¹; ¹H NMR (CDCl₃): δ 7.46 (dd, *J*_{H,F} = 6.6 Hz, *J*_{m-H} = 1.8 Hz, 1, ArH), 7.40–7.24 (m, 5, ArH), 7.08 (td, *J*_{H,F} = 8.7 Hz, *J*_{m-H} = 2.1 Hz, 1, ArH), 6.46 (s, 1, CHO). ¹³C nmr (CDCl₃): δ 168.2, 164.1, 157.2, 134.7, 129.9, 129.2, 128.4, 127.2, 126.4, 110.4, 108.8, 80.7. Mass Spec: *m/z* = 246 (M⁺).

Anal. Calcd for C₁₄H₈F₂O₂: C, 68.29; H, 3.25. Found: C, 68.63; H, 3.56.

4,6-Dichloro-3-(2-furyl)isobenzofuran-1(3H)-one (4c) was isolated as an off-white solid (chromatography), ⁹mp. 115.5–117°C; IR: 1778 (lactone) cm⁻¹; ¹H NMR (CDCl₃): δ 7.83 (d, *J*_{m-H} = 1.5 Hz, 1, ArH), 7.63 (d, *J*_{m-H} = 1.5 Hz, 1, ArH), 7.38 (dd, *J*_{furanH2,H3} = 2.0 Hz, *J*_{furanH2,H4} = 0.8 Hz, 1, ArH), 6.50 (dd, *J*_{furanH4,H3} = 3.3 Hz, *J*_{furanH4,H2} = 0.6 Hz, 1, ArH), 6.40 (s, 1, CHO), 6.39 (dd, *J*_{furanH3,H4} = 3.6 Hz, *J*_{furanH3,H2} = 1.8 Hz, 1, ArH). ¹³C nmr (CDCl₃): δ 167.5, 146.1, 144.5, 142.1, 137.4, 134.8, 130.8, 130.2, 124.5, 112.6, 111.1, 74.8. Mass Spec: *m/z* = 268 (M⁺).

Anal. Calcd for C₁₂H₆Cl₂O₃: C, 53.56; H, 2.25. Found: C, 53.27; H, 2.25.

4,6-Difluoro-3-(2-furyl)isobenzofuran-1(3H)-one (4d) was isolated as a pale yellow oil (chromatography); IR: 3525 (hydrate); 1777 (lactone) cm⁻¹; ¹H nmr (CDCl₃): δ 7.47 (dd, *J*_{H,F} = 6.6 Hz, *J*_{m-H} = 1.8 Hz, 1, ArH), 7.41 (m, 1, furanH₂), 7.13 (td, *J*_{H,F} = 8.6 Hz, *J*_{m-H} = 1.8 Hz, 1, ArH), 6.48 (s, 1, CHO), 6.46 (d, *J*_{furanH4,H3} = 3.3 Hz, 1, ArH), 6.39 (dd, *J*_{furanH3,H4} = 3.3 Hz, *J*_{furanH3,H2} = 1.8 Hz, 1, ArH). ¹³C nmr (CDCl₃): δ 168.0, 164.5, 157.3, 146.1, 144.6, 129.0, 128.4, 111.5, 111.2, 110.1, 108.9, 73.3. Mass Spec: *m/z* = 236 (M⁺).

Anal. Calcd for C₁₂H₆F₂O₃·1/3H₂O: C, 59.55; H, 2.76. Found: C, 59.77; H, 3.25.

4,6-Dichloro-3-(2-thienyl)isobenzofuran-1(3H)-one (4e) was isolated as an off-white solid (trituration/chromatography), mp. 107.5–109.5°C; IR: 1774 (lactone) cm⁻¹; ¹H nmr (CDCl₃): δ 7.84 (d, *J*_{m-H} = 1.8 Hz, 1, ArH), 7.64 (d, *J*_{m-H} = 1.5 Hz, 1, ArH), 7.38 (dd, *J*_{H2,H3} = 5.4 Hz, *J*_{H2,H4} = 0.9 Hz, 1, ArH), 7.14 (dd, *J*_{H4,H3} = 3.6 Hz, *J* = 1.2 Hz, 1, ArH), 7.01 (dd, *J*_{H3,H2} = 5.1 Hz, *J*_{H3,H4} = 3.6 Hz, 1, ArH), 6.63 (s, 1, CHO). ¹³C nmr (CDCl₃): δ 167.3, 144.1, 137.4, 136.4, 135.0, 130.9, 129.4, 128.2, 127.3, 127.1, 124.4, 77.2. Mass Spec: *m/z* = 284 (M⁺).

Anal. Calcd for C₁₂H₆Cl₂O₂S: C, 50.54; H, 2.12. Found: C, 50.83; H, 2.31.

4,6-Difluoro-3-(2-thienyl)isobenzofuran-1(3H)-one (4f) was isolated as a yellow oil (chromatography); IR: 1774 (lactone) cm⁻¹; ¹H NMR (CDCl₃): δ 7.46 (dd, *J*_{H,F} = 6.6 Hz, *J*_{m-H} = 2.1 Hz, 1, ArH), 7.37 (dd, *J*_{thiopheneH2,H2} = 5.1 Hz, *J*_{thiopheneH2,H4} = 1.2 Hz, 1, ArH),

7.16 (dd, $J_{\text{thiopheneH4,H3}} = 3.0$ Hz, $J_{\text{thiopheneH4,H2}} = 1.2$ Hz, 1, ArH), 7.13 (td, $J_{\text{H,F}} = 6.6$ Hz, $J_{\text{m-H}} = 2.1$ Hz, 1, ArH), 7.02 (dd, $J_{\text{thiopheneH3,H2}} = 5.1$ Hz, $J_{\text{thiopheneH3,H4}} = 3.0$ Hz, 1, ArH), 6.72 (s, 1, CHO). ^{13}C nmr (CDCl_3): δ 167.4, 164.4, 157.3, 151.0, 137.1, 130.4, 128.8, 127.9, 127.5, 110.5, 108.9, 75.8. Mass Spec: $m/z = 252$ (M^+).

Anal. Calcd for $\text{C}_{12}\text{H}_6\text{F}_2\text{O}_2\text{S} \cdot 1/3\text{C}_6\text{H}_{14}$: C, 59.86; H, 3.80. Found: C, 59.91; H, 3.81.

4,6-Dichloro-3-(*p*-anisyl)isobenzofuran-1(3H)-one (4g) was isolated as a white solid (trituration/chromatography), mp. 107.5–109°C; IR: 1773 (lactone) cm^{-1} ; ^1H NMR (CDCl_3): δ 7.84 (d, $J_{\text{m-H}} = 1.5$ Hz, 1, ArH), 7.59 (d, $J_{\text{m-H}} = 1.8$ Hz, 1, ArH), 7.10 (d, $J_{\text{a,b}} = 9.0$ Hz, 2, ArH), 6.86 (d, $J_{\text{b,a}} = 9.0$ Hz, 2, ArH), 6.32 (s, 1, CHO), 3.79 (s, 3, OCH_3). ^{13}C nmr (CDCl_3): δ 169.0, 160.8, 145.0, 136.9, 134.8, 130.7, 129.8, 129.7, 125.6, 124.2, 114.4, 82.4, 55.5. Mass Spec: $m/z = 308$ (M^+).

Anal. Calcd for $\text{C}_{15}\text{H}_{10}\text{Cl}_2\text{O}_3$: C, 58.28; H, 3.26. Found: C, 58.30; H, 3.31.

4,6-Difluoro-3-(*p*-anisyl)isobenzofuran-1(3H)-one (4h) was isolated as a white solid (chromatography), mp. 100–103°C. IR: 1764 (lactone) cm^{-1} ; ^1H NMR (CDCl_3): δ 7.45 (dd, $J_{\text{H,F}} = 6.6$ Hz, $J_{\text{m-H}} = 2.1$ Hz, 1, ArH), 7.16 (d, $J_{\text{a,b}} = 9.0$ Hz, 2, ArH), 7.07 (td, $J_{\text{H,F}} = 8.6$ Hz, $J_{\text{m-H}} = 2.0$ Hz, 1, ArH), 6.88 (d, $J_{\text{b,a}} = 9.0$ Hz, 2, ArH), 6.42 (s, 1, CHO), 3.79 (s, 3, OCH_3). ^{13}C nmr (CDCl_3): δ 168.3, 166.6, 160.9, 157.7, 131.5, 129.6, 128.8, 126.5, 114.6, 110.3, 108.7, 80.7, 55.6. Mass Spec: $m/z = 276$ (M^+).

Anal. Calcd for $\text{C}_{15}\text{H}_{10}\text{F}_2\text{O}_3$: C, 65.22; H, 3.62. Found: C, 65.44; H, 3.59.

References

1. G. Pagani, G. Caccialanza, and F. Bona, *Farmaco Sci.*, **33**, 618 (1978).
2. S. Richards, B. Sorensen, H-s. Jae, M. Winn, Y. Chen, J. Wang, S. Fung, K. Monzon, E. U. Frevert, P. Jacobson, H. Sham, and J. T. Link, *Bioorg. Med. Chem. Lett.*, **16**, 6241 (2006).
3. T. Guo, R. C. Hunter, H. Gu, H. L. L. Rokosz, T. M. Stauffer, and D. W. Hobbs, *Bioorg. Med. Chem. Lett.*, **15**, 3691 (2005).
4. L. B. Fertel and J. J. Maul, *Difluorophthalic Compounds and their Preparation*, US Patent 5,405,995, April 11, 1995; *Chem. Abstr.*, **123**, 111850 (1995).
5. M. Demas, G. J. Javadi, L. M. Bradley, and D. A. Hunt, *J. Org. Chem.*, **65**, 7201 (2000).
6. M. R. Boyd, C. Farina, P. Belfiore, S. Gagliardi, J. W. Kim, Y. Hayakawa, J. A. Beutler, T. C. McKee, B. J. Bowman, and E. J. Bowman, *J. Pharmacol. Exp. Ther.*, **297**, 114 (2001).
7. Snieckus, V. *Chem. Rev.*, **90**, 879 (1990) and references contained within.
8. P. C. Conrad, P. L. Kwiatkowski, and P. L. Fuchs, *J. Org. Chem.*, **52**, 586 (1987).
9. Several attempts to acquire combustion analysis data within the normal tolerance of 0.30 for **4d** failed. Apparently this compound deteriorates very rapidly as evidenced by the fact that its exact mass was not observed by HR mass spectral analysis (TOF-MS).